Zacks Research Has Positive View of HealthEquity Q2 Earnings

HealthEquity, Inc. (NASDAQ:HQY) – Research analysts at Zacks Research increased their Q2 2026 EPS estimates for HealthEquity in a report released on Tuesday, June 24th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.70 per share for the quarter, up from their previous estimate of $0.68. The consensus estimate for HealthEquity’s current full-year earnings is $2.32 per share. Zacks Research also issued estimates for HealthEquity’s Q3 2026 earnings at $0.73 EPS, Q4 2026 earnings at $0.76 EPS, FY2026 earnings at $3.05 EPS, Q1 2027 earnings at $0.81 EPS, Q4 2027 earnings at $0.96 EPS, FY2027 earnings at $3.59 EPS, Q1 2028 earnings at $0.99 EPS and FY2028 earnings at $4.18 EPS.

HQY has been the topic of several other research reports. The Goldman Sachs Group boosted their price target on shares of HealthEquity from $94.00 to $104.00 and gave the company a “neutral” rating in a research report on Wednesday, June 4th. Wall Street Zen raised shares of HealthEquity from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. Barrington Research boosted their price target on shares of HealthEquity from $112.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, June 5th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of HealthEquity from $98.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, June 5th. Finally, Raymond James Financial raised shares of HealthEquity from an “outperform” rating to a “strong-buy” rating and lowered their price target for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $118.09.

HealthEquity Stock Performance

Shares of HQY stock opened at $104.88 on Friday. The firm has a market cap of $9.07 billion, a price-to-earnings ratio of 76.55, a P/E/G ratio of 1.61 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.06 and a current ratio of 4.06. HealthEquity has a 52 week low of $65.01 and a 52 week high of $116.65. The firm’s 50-day simple moving average is $98.01 and its two-hundred day simple moving average is $98.00.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.81 by $0.16. The business had revenue of $330.80 million for the quarter, compared to analyst estimates of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same quarter in the previous year, the firm posted $0.80 earnings per share.

Insider Buying and Selling

In related news, EVP Michael Henry Fiore sold 8,881 shares of the company’s stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the sale, the executive vice president now owns 56,655 shares of the company’s stock, valued at approximately $4,433,820.30. This represents a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Elimelech Rosner sold 58,000 shares of the company’s stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $112.56, for a total transaction of $6,528,480.00. Following the sale, the executive vice president now directly owns 75,689 shares in the company, valued at $8,519,553.84. This trade represents a 43.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 304,581 shares of company stock valued at $33,664,018. Company insiders own 1.50% of the company’s stock.

Institutional Trading of HealthEquity

Hedge funds and other institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc purchased a new position in HealthEquity in the 1st quarter worth approximately $28,000. WPG Advisers LLC purchased a new position in HealthEquity in the 1st quarter worth approximately $28,000. Transce3nd LLC purchased a new position in HealthEquity in the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC grew its stake in HealthEquity by 34.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company’s stock worth $37,000 after buying an additional 98 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in HealthEquity in the 4th quarter worth approximately $39,000. Institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.